Despoina Pantazi

Dr. Despoina Pantazi

Chemistry, University of Ioannina, Ioánnina, Ípeiros, Greece
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

Verified
Journal Article
Open access
PDF file
PAPetros-Spyridonas Adamidis
Petros-Spyridonas Adamidis
Despoina PantaziDespoina Pantazi
Despoina Pantazi
IMIraklis Moschonas
Iraklis Moschonas
Evangelos LiberopoulosEvangelos Liberopoulos
Evangelos Liberopoulos
Alexandros D. TselepisAlexandros D. Tselepis
Alexandros D. Tselepis
Neutrophil extracellular traps (NETs) have attracted much attention recently, beyond elemental host immunity, due to their fundamental implication in a variety of pathologic conditions and widespread impactful diseases. Atherosclerotic cardiovascular disease (ASCVD) is one of them, and a major cause of mortality and disability worldwide. Consequently, years of basic and clinical research were dedicated to shedding light on every possible pathophysiologic mechanism that could be used as an effective prevention and treatment tool to ameliorate its burden. This led to the development of complex and prevention protocols and regimens that are now widely used, with lipid-lowering treatment being the current cornerstone; however, this is not adequate to alleviate the residual cardiovascular risk, which remains prominent. Despite the demonstrated pathogenic role of NETs in the progression and complications of ASCVD, little is known about their potential as a therapeutic target and the effects hypolipidemics exert on them.

12 June 2024 in Current Treatment Options in Oncology
Verified
Journal Article
Closed access
PDF file
Despoina PantaziDespoina Pantazi
Despoina Pantazi
DADimitrios Alivertis
Dimitrios Alivertis
ATAlexandros D. Tselepis
Alexandros D. Tselepis

2 June 2013 in Lipids
Verified
Journal Article
Closed access
PDF file
Despoina PantaziDespoina Pantazi
Despoina Pantazi
EKEIRINI KITSIOULI
EIRINI KITSIOULI
AKAthanasios Karkabounas
Athanasios Karkabounas
TTTheoni Trangas
Theoni Trangas
GNGeorge Nakos
George Nakos
MLMarilena E. Lekka
Marilena E. Lekka

Verified
Journal Article
Open access
PDF file
IKIoannis Koutsaliaris
Ioannis Koutsaliaris
Despoina PantaziDespoina Pantazi
Despoina Pantazi
ATAikaterini Tsouka
Aikaterini Tsouka
OAOurania Argyropoulou
Ourania Argyropoulou
Tellis ConstantinosTellis Constantinos
Tellis Constantinos
Alexandros D. TselepisAlexandros D. Tselepis
Alexandros D. Tselepis
The omega-3 polyunsaturated fatty acids (PUFAs) Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA) exert multiple cardioprotective effects, influencing inflammation, platelet activation, endothelial function and lipid metabolism, besides their well-established triglyceride lowering properties. It is not uncommon for omega-3 PUFAs to be prescribed for hypertriglyceridemia, alongside antiplatelet therapy in cardiovascular disease (CVD) patients. In this regard, we studied the effect of EPA and DHA, in combination with antiplatelet drugs, in platelet aggregation and P-selectin and αIIbβ3 membrane expression. The antiplatelet drugs aspirin and triflusal, inhibitors of cyclooxygenase-1 (COX-1); ticagrelor, an inhibitor of the receptor P2Y12; vorapaxar, an inhibitor of the PAR-1 receptor, were combined with DHA or EPA and evaluated against in vitro platelet aggregation induced by agonists arachidonic acid (AA), adenosine diphosphate (ADP) and TRAP-6. We further investigated procaspase-activating compound 1 (PAC-1) binding and P-selectin membrane expression in platelets stimulated with ADP and TRAP-6. Both DHA and EPA displayed a dose-dependent inhibitory effect on platelet aggregation induced by AA, ADP and TRAP-6. In platelet aggregation induced by AA, DHA significantly improved acetylsalicylic acid (ASA) and triflusal’s inhibitory activity, while EPA enhanced the inhibitory effect of ASA. In combination with EPA, ASA and ticagrelor expressed an increased inhibitory effect towards ADP-induced platelet activation. Both fatty acids could not improve the inhibitory effect of vorapaxar on AA- and ADP-induced platelet aggregation. In the presence of EPA, all antiplatelet drugs displayed a stronger inhibitory effect towards TRAP-6-induced platelet activation. Both omega-3 PUFAs inhibited the membrane expression of αIIbβ3, though they had no effect on P-selectin expression induced by ADP or TRAP-6. The antiplatelet drugs exhibited heterogeneity regarding their effect on P-selectin and αIIbβ3 membrane expression, while both omega-3 PUFAs inhibited the membrane expression of αIIbβ3, though had no effect on P-selectin expression induced by ADP or TRAP-6. The combinatory effect of DHA and EPA with the antiplatelet drugs did not result in enhanced inhibitory activity compared to the sum of the individual effects of each component.

8 March 2021 in Angiology
Verified
Journal Article
Closed access
PDF file
SSSofia Sidiropoulou
Sofia Sidiropoulou
SPStyliani Papadaki
Styliani Papadaki
ATAikaterini N. Tsouka
Aikaterini N. Tsouka
IKIoannis K. Koutsaliaris
Ioannis K. Koutsaliaris
VCVasileios G. Chantzichristos
Vasileios G. Chantzichristos
Alexandros D. TselepisAlexandros D. Tselepis
Alexandros D. Tselepis
Platelets mediate circulating endothelial progenitor cell (EPC) recruitment and maturation, participating in vascular repair, however the underlying mechanism(s) remain unclear. We investigated the effect of platelet-rich plasma (PRP) on the functionality of CD34 + -derived late-outgrowth endothelial cells (OECs) in culture. Confluent OECs were coincubated with PRP under platelet aggregation (with adenosine diphosphate; ADP) and nonaggregation conditions, in the presence/absence of the reversible P2Y12 platelet receptor antagonist ticagrelor. Outgrowth endothelial cell activation was evaluated by determining prostacyclin (PGI 2 ) and monocyte chemoattractant protein-1 (MCP-1) release and intercellular adhesion molecule-1 (ICAM-1) membrane expression. Similar experiments were performed using human umbilical vein endothelial cells (HUVECs). Platelet-rich plasma increased ICAM-1 expression and PGI 2 and MCP-1 secretion compared with autologous platelet-poor plasma, whereas ADP-aggregated platelets in PRP did not exhibit any effect. Platelet-rich plasma pretreated with ticagrelor prior to activation with ADP increased all markers to a similar extent as PRP. Similar results were obtained using HUVECs. In conclusion, PRP induces OEC activation, a phenomenon not observed when platelets are aggregated with ADP. Platelet inhibition with ticagrelor restores the PRP capability to activate OECs. Since EPC activation is important for endothelial regeneration and angiogenesis, we suggest that agents inhibiting platelet aggregation, such as ticagrelor, may promote platelet-EPC interaction and EPC function.